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Is metformin and spironolactone better 
than metformin alone for improving 




Likely not. Metformin 1000-1700mg/day combined with low-dose spironolactone 25-50mg/day 
shows a greater reduction in hirsutism scores among patients with PCOS than metformin alone 
however similar symptom scores between groups at follow-up suggest the effect is not clinically 
significant (SOR: B, RCTs).  In addition, combination therapy leads to inconsistent improvement 
in menstrual regularity. 
 
Evidence summary 
A 2013 RCT (N=198) studied the efficacy of metformin and low-dose spironolactone in 
management of PCOS symptoms¹. Women with a mean age of 23 who met the 2006 Androgen 
Excess-PCOS criteria were allocated to 3 different treatment groups, metformin (1000mg/day) 
plus low-dose spironolactone (50mg/day) or each drug alone. All women had menstrual 
irregularities defined as oligomenorrhea (menstrual interval greater than or equal to 35 days or 
less than 8 cycles per year) or amenorrhea (no cycle in the last 6 months or more). Hirsutism was 
evaluated by a modified FGS score at baseline, 3 months, and 6 months performed by a single 
observer with a score greater than 7 deemed significant hirsutism.  At 6 months, FGS scores 
improved from 13 to 9.7 (P=.001) in the metformin group, and from 14 to 9.6 (P=.001) in the 
spironolactone group. Combination therapy resulted in a greater improvement in FGS scores 
compared to either drug alone, 13 to 9.1 at 6 months (p<.05). Though the improvement reached 
statistical significance in the combination therapy group, 6 month symptom scores are similar 
between groups and may not reflect clinical significance. Cycle frequency at six months 
improved from 6.0 to 10 cycles per year (P=.01) in the metformin group, from 6.5 to 10 cycles 
per year (P=.001) in the spironolactone group and from 6.1 to 12 cycles per year (P=.01) in the 
combination therapy group but the differences between groups were not significant. Participant 
withdrawal due to side effects (gastrointestinal symptoms and menstrual irregularities) was 
comparable between groups. Results are limited by small sample size, lack of blinding in FGS 
evaluation at follow-up and lack of a placebo group. 
A 2013 RCT (N=56) examined the effect of metformin (1700mg/day) and low-dose 
spironolactone (25mg/day) versus metformin alone on symptoms of PCOS². Enrolled patients 
had an average age of 23 years and PCOS as defined by Rotterdam criteria. The Ferriman-
Gallway score (FGS) of hirsutism severity was used to assess hirsutism with scores greater than 
8 indicating hirsutism presence and scores greater than 15 indicating moderate to severe 
hirsutism.  Patients in this study had an average FGS of 14 along with either mild 
oligomenorrhea (7−8 cycles/year) or moderate to severe oligomenorrhea (less than 6 
cycles/year). FGS scores were repeated at 6 months post intervention with improvements in both 
the metformin plus low-dose spironolactone group (15 to 11, P<.001) and metformin alone 
groups (12 to 11, P<.001). While improvement in the combination group was statistically 
significant in comparison to the metformin group (P<.001), it is likely not clinically significant 
as 6 month scores are similar between groups. Improvement is most likely explained by baseline 
differences between groups FGS scores. Menstrual cycles normalized in 82% of patients treated 
with metformin (P<.001) and 67% of patients in patients receiving combination therapy 
(P<.001). Differences between groups were not statistically significant. This study is limited by 
small sample size, difference in baseline FGS scores between groups and lack of placebo control 
group. 
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